2023
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, Philley J, Desruisseaux M, Keller M, Hochman J, Pirofski L, Ortigoza M, Hochman J, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Ortigoza M, Pirofski L, Yoon H, Sturm-Reganato C, Cobb G, Andela R, Darwish Y, Taveras M, Xin P, LaFleur J, Cleare L, Goldfeld K, Li Y, Ortigoza M, O'Keeffe M, Cobb G, Sturm-Reganato C, Rahman F, Ajayi A, Rodriguez S, Iturrate E, Gallagher J, Thomas O, Ramos D, Fong C, Pirofski L, Yoon H, Keller M, Asencio A, Eke I, Castro J, Shan J, Chalco A, LaFleur J, Cleare L, Desruisseaux M, Cortezzo G, Rocco E, Ndunge O, Parmelee C, Solomon G, Cahil S, Jayaweera D, Lee C, Ransford D, Dasmany D, Corona A, Moreno K, Martinez G, Otero C, McPherson D, Ostrosky-Zeichner L, Patel B, Nigo M, Huebinger R, Dronavalli G, Grimes C, Umana V, Hernandez M, Nielsen L, Stutz T, Mammadova M, Dentino A, Heath T, Martin J, Bello F, Hinojosa E, Philley J, Devine M, Hibbard R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases 2023, 11: ofad686. PMID: 38269049, PMCID: PMC10807994, DOI: 10.1093/ofid/ofad686.Peer-Reviewed Original ResearchPost-acute sequelaePROMIS scoresCOVID-19 convalescent plasma (CCP) therapySARS-CoV-2 infection symptomsSARS-CoV-2 infectionAcute COVID-19Convalescent plasma therapyGlobal health assessmentPhysical health scoresCOVID-19 hospitalizationCOVID-19 trialsSelf-reported symptomsRespective reference groupsRace/ethnicityPASC symptomsRandomization armAcute infectionAcute treatmentPlasma therapyGeneral symptomsSymptom SurveyLong-term effectsHealth scoresOverall healthDisease severity
2021
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Thompson M, Henderson J, Shah P, Rubinstein S, Joyner M, Choueiri T, Flora D, Griffiths E, Gulati A, Hwang C, Koshkin V, Papadopoulos E, Robilotti E, Su C, Wulff-Burchfield E, Xie Z, Yu P, Mishra S, Senefeld J, Shah D, Warner J, Halmos B, Verma A, Gartrell B, Goel S, Ohri N, Sica R, Thakkar A, Stockerl-Goldstein K, Butt O, Campian J, Fiala M, Monahan R, Zhou A, Bohachek P, Mundt D, Streckfuss M, Tadesse E, Lammers P, Revankar S, Panagiotou O, Egan P, Farmakiotis D, Khan H, Olszewski A, Loaiza-Bonilla A, Del Prete S, Angevine A, Bar M, Lo K, Stratton J, Weinstein P, Caimi P, Barnholtz-Sloan J, Garcia J, Nakayama J, Gupta S, Pennell N, Ahluwalia M, Dawsey S, Nizam A, Lemmon C, Hoppenot C, Li A, Bakouny Z, Bouchard G, Busser F, Conners J, Curran C, Demetri G, Giordano A, Kelleher K, Nohria A, Schmidt A, Shaw G, Van Allen E, Nuzzo P, Xu W, Zon R, Zhang T, Halabi S, Lyman G, Graber J, Grivas P, Khaki A, Loggers E, Lynch R, Nakasone E, Schweizer M, Tachiki L, Vinayak S, Wagner M, Yeh A, Gatson N, Goyal S, Huynh-Le M, Rosenstein L, Clement J, Daher A, Dailey M, Elias R, Hsu E, Menendez A, Rathmann J, Serrano O, Jayaraj A, Gadgeel S, Hawley J, Hershman D, Accordino M, Bhutani D, Schwartz G, Reuben D, Mushtaq S, Bernicker E, Deeken J, Shafer D, Lewis M, Rhodes T, Gill D, Low C, Nagle S, Hayes-Lattin B, McWeeney S, Nemecek E, Zaren H, Smith S, Nagaraj G, Akhtari M, Lau E, Reeves M, Berg S, Elms D, Morgans A, Wehbe F, Altman J, Gurley M, Mulcahy M, Durbin E, Kulkarni A, Nelson H, Shah S, Rosovsky R, Reynolds K, Bardia A, Boland G, Gainor J, Zubiri L, Halfdanarson T, Bekaii-Saab T, Desai A, Mesa R, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Belenkaya R, Philip J, Riely G, Faller B, McKay R, Ajmera A, Cabal A, Shaya J, Weissmann L, Jani C, Chen J, Gatti-Mays M, Jhawar S, Lustberg M, Palmer J, Pillainayagam C, Stover D, Wall S, Williams N, Karivedu V, Addison D, Joshi M, Menon H, Rovito M, Elshoury A, Jabbour S, Shah M, Bashir B, Mahmood S, McNair C, Mico V, Rivera A, Miller C, Cabebe E, Glover M, Jha A, Schapira L, Shah S, Wu J, Subbiah S, Logan B, Kloecker G, Lopes G, Russell K, Stith B, Smits M, Edwin N, Chism D, Owenby S, Doroshow D, Galsky M, Zhu H, Fu J, Fazio A, Patel K, Riess J, Kwon D, Kumar V, Islam J, Wood W, Ahmad S, Grover P, Gulati S, Kharofa J, Marcum M, Park C, Wise-Draper T, Bowles D, Geiger C, Bishnoi R, Markham M, Shah C, Acoba J, Rho Y, Feldman L, Hoskins K, Gantt G, Khan M, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Kasi A, Fecher L, Friese C, Mavromatis B, Zaman Q, Bijjula R, Cheng A, Davis E, French B, Gillaspie E, Hausrath D, Hennessy C, Hsu C, Johnson D, Li X, Reid S, Rini B, Shyr Y, Slosky D, Solorzano C, Tucker M, Vega-Luna K, Wang L, Enriquez K, Sun T, Carducci T, Puc M, Van Loon S, Goldsmith K, Rice R, Cabalona W, Pilar C, Barrow McCollough B, Peddi P, Rosen L, Bilen M, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Masters T, Stratton C. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology 2021, 7: 1167-1175. PMID: 34137799, PMCID: PMC8377563, DOI: 10.1001/jamaoncol.2021.1799.Peer-Reviewed Original ResearchConvalescent plasma recipientsConvalescent plasma treatmentConvalescent plasma therapyMechanical ventilatory supportHematologic cancersPlasma recipientsVentilatory supportCohort studyHazard ratioPlasma therapyMAIN OUTCOMECOVID-19Intensive care unit admissionProportional hazards regression analysisPropensity scoreUntreated control patientsCare unit admissionRetrospective cohort studySevere COVID-19Potential survival benefitHazards regression analysisMulti-institutional cohortSecondary subgroup analysisIntensive care unitPotential confounding factorsTreatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials
Han Y, Lee K, Yoon S, Nam S, Ryu S, Seong D, Kim J, Lee J, Yang J, Lee J, Koyanagi A, Hong S, Dragioti E, Radua J, Smith L, Oh H, Ghayda R, Kronbichler A, Effenberger M, Kresse D, Denicolò S, Kang W, Jacob L, Shin H, Shin J. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics 2021, 11: 1207-1231. PMID: 33391531, PMCID: PMC7738873, DOI: 10.7150/thno.48342.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAlanineAnimalsAntiviral AgentsCarbamatesCoronavirus InfectionsCOVID-19COVID-19 SerotherapyDisease Models, AnimalDrug CombinationsDrug Evaluation, PreclinicalDrug Therapy, CombinationHumansImidazolesImmunization, PassivePyrrolidinesRandomized Controlled Trials as TopicSevere Acute Respiratory SyndromeSofosbuvirTreatment OutcomeValineConceptsRandomized Controlled TrialsSevere acute respiratory syndromeMiddle East respiratory syndromeSystematic review of in vitroReview of in vitroTherapeutic agentsAcute respiratory syndromeTreatment of severe acute respiratory syndromeConvalescent plasma therapySystematic reviewMeta-analysesRespiratory syndromePlasma therapyClinical studiesClinical trialsTherapeutic effectControlled TrialsSyndromeTherapyCoronavirus disease 2019In vivoTreat COVID-19COVID-19Relevant publicationsTreatment
2020
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen F, Amanat F, Stadlbauer D, Altman D, Chen B, Krammer F, Mendu D, Firpo-Betancourt A, Levin M, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang J, Arinsburg S, Reich D, Aberg J, Bouvier N. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine 2020, 26: 1708-1713. PMID: 32934372, DOI: 10.1038/s41591-020-1088-9.Peer-Reviewed Original ResearchConceptsPlasma recipientsSARS-CoV-2Convalescent plasmaLife-threatening COVID-19Suppress virus replicationConvalescent plasma therapyEffectiveness of convalescent plasma therapyScore-matched controlsVirus-specific antibodiesMount Sinai HospitalRandomized Controlled TrialsPlasma therapySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Controlled studiesAcellular componentsControlled TrialsSyndrome coronavirus 2Sinai HospitalAntiviral effectPatientsOxygen requirementVirus replicationAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply